J&J Quickly Advances BCMA-Targeting CAR-T As JNJ-4528 Shows 100% Response

 
• By Mandy Jackson

Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.

3d illustration of T cells or cancer cells
Myeloma patients have responded well to T-cells engineered to target BCMA. • Source: Shutterstock

More from Anticancer

More from Therapy Areas